Kestra Medical Technologies (NASDAQ:KMTS) Trading Up 7.5% – Should You Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price traded up 7.5% during mid-day trading on Wednesday . The company traded as high as $26.47 and last traded at $27.36. Approximately 17,413 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 327,786 shares. The stock had previously closed at $25.44.

Analysts Set New Price Targets

KMTS has been the subject of several recent analyst reports. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. BTIG Research reissued a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Finally, The Goldman Sachs Group cut their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average target price of $27.40.

Kestra Medical Technologies Price Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The business’s 50 day moving average price is $21.20 and its 200 day moving average price is $22.78. The stock has a market capitalization of $1.60 billion, a P/E ratio of -6.95 and a beta of 0.83.

Insiders Place Their Bets

In other news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider directly owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 45,000 shares of company stock worth $927,150. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KMTS. California State Teachers Retirement System lifted its stake in shares of Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares during the period. The Manufacturers Life Insurance Company grew its position in Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after buying an additional 5,731 shares during the period. Quantinno Capital Management LP purchased a new stake in Kestra Medical Technologies during the first quarter valued at approximately $431,000. Sei Investments Co. raised its position in Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares during the period. Finally, Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $603,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.